CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial-Reference-Cited by-同舟云学术

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

Published:2017-07 Issue:7 Volume:18 Page:917-928
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Stebbing Justin,Baranau Yauheni,Baryash Valeriy,Manikhas Alexey,Moiseyenko Vladimir,Dzagnidze Giorgi,Zhavrid Edvard,Boliukh Dmytro,Stroyakovskii Daniil,Pikiel Joanna,Eniu Alexandru,Komov Dmitry,Morar-Bolba Gabriela,Li Rubi K,Rusyn Andriy,Lee Sang Joon,Lee Sung Young,Esteva Francisco J

Publisher

Elsevier BV

Subject

Oncology

Reference42 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. HER2-positive breast cancer: update on new and emerging agents;Drakaki;Am J Hematol Oncol,2015

3. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry;Esteva;Pathol Oncol Res,2001

4. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer;Buzdar;J Clin Oncol,2005

5. Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infusion Reactions in HER2-Positive Gastric Cancer: Switching from Trastuzumab to Its Biosimilar;Biological and Pharmaceutical Bulletin;2024-08-21

2. Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies;JCO Oncology Practice;2024-08

3. Revisions to the requirement of the Japanese clinical study data for biosimilar developments in Japan;Expert Opinion on Biological Therapy;2024-07-02

4. Define Critical Parameters of Trastuzumab-Mediated ADCC Assays via Assay Optimization Processes, Focusing on the Impact of Cryopreserved Effector Cells on Assay Performance;Cancers;2024-06-27

5. Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study;Clinical Drug Investigation;2024-06-27